Össur Acquires Naked Prosthetics

It is a welcome addition to the Össur product portfolio as it strengthens Össur's upper limb product offering globally and allows Össur to address a broader group of amputees seeking to live a Life Without Limitations.

Össur has acquired Naked Prosthetics, a leading provider of durable, custom and functional finger prostheses for finger and partial hand amputees, with effect from 26 August 2022. The mechanical devices are individually designed to mimic the natural motion of the finger.

The acquisition addresses a critical need for patients with finger and partial hand loss, traditionally an underserved yet growing population. It is a welcome addition to the Össur product portfolio as it strengthens Össur’s upper limb product offering globally and allows Össur to address a broader group of amputees seeking to live a Life Without Limitations.

The Company has around 70 employees and is located in the US, in Olympia, Washington. In 2021, Naked Prosthetics’ sales amounted to USD 9 million.

The acquisition will not have an impact on the financial guidance provided for the full year.

Sveinn Sölvason, President and CEO of Össur:

“Naked Prosthetics has developed functional and high-quality finger prostheses that complement our product portfolio and add an important range to our upper limb product offering. The acquisition strengthens our global market position, and we are pleased to welcome the employees of Naked Prosthetics to the Össur team.”

Bob Thompson, CEO of Naked Prosthetics:

“Össur’s global reach and expertise make them an obvious and welcome next step for Naked Prosthetics’ goal of getting more finger amputees back to work and doing what they love. We are excited to join forces with the Össur team and continue to grow the partial-hand prosthetic market.”

More

CorWave Completes 6-Month In Vivo Study for Clinical Trials Initiation

In vivo studies demonstrated the pump’s successful operation for a period of up to six months. Additionally, nine chronic ovine implants were conducted for 60 days with no device failure or sign of thrombosis at explant. These significant milestones mark the final stage of CorWave’s preclinical development, paving the way for its First-In-Human study.